Restoring the Permanently Lost Foundation Guild™ is Possible.

Notitia's proprietary Foundation Guild™ Microbiome R&D Platform allows us to develop unique and effective treatments for various diseases and complications. Under our Foundation Guild™ Clinical Program, we currently have two leading drug candidates being tested in multiple clinical conditions. Our R&D platform allows us to launch additional conditions or drugs quickly and effectively.

Bacterial Medicine (BM306)

BM306 is an investigational live biotherapeutic product that contains the Foundation Guild™ bacteria in a defined consortium. This investigational drug is designed to treat diseases by replenishing the missing or extinct Foundation Guild™ bacteria in a patient's gut microbiome.

Nutritional Medicine (NM108)

NM108 is an investigational botanical drug that is designed to treat diseases by promoting the growth of either the existing or replenished Foundation Guild™ bacteria in a patient's gut microbiome.

NM108 is currently in phase 2 trial as well as available for Expanded Access (compassionate use). If you are interested in receiving this product, please contact us at ExpandedAccess@notitabio.com

Clinical Pipeline

Condition Pre-clinical Phase
1		 Phase
2		 Phase
3
Functional Gastrointenstinal Disorder (FGID) in Long COVID-19 patients Completed Completed in-progress

Links to studies
Multiple Sclerosis (MS) Completed Completed

Links to studies
Parkinson's Disease Completed Completed
Early/End-stage Diabetic Kidney Disease (DKD) Completed Completed
Side-effects of Cancer Chemotherapy Completed Completed
Prader-Willi Syndrome (PWS) Completed
If you are a patient who is interested in joining our ongoing clinical trial, please visit ClinicalTrials.gov for more information.
If you are a physician or patient who is interested in joining our Expanded Access Program (Compassionate Use), please contact us at ExpandedAccess@notitabio.com


For more information on the FDA Expanded Access Program, please visit the official FDA website.